Insights from dermatology, pulmonary disease, and endometriosis on the role of functional relevance in inflammation and translatability to the clinic.
Inflammatory diseases and efficiency of therapeutic strategy in these diseases are often evaluated through what can be measured in tissue: lesion size, immune cell infiltration, or molecular markers of pathway activation. These readouts are essential for understanding disease biology and compound pharmacology, however, they rarely capture how inflammation is experienced by patients, and how much relief a treatment could provide. In practice, disease burden is defined by functional disruption such as itching, coughing, fatigue, impaired organ performance, or pain, which may only partially align with structural pathology and biological readouts.
This disconnect is apparent across multiple inflammatory indications. For example, in dermatological disease, inflammation frequently presents as itch, a symptom that can dominate patient experience despite relatively modest visible pathology. Functional behavioral readouts, such as monitoring scratching frequency and duration in research models, provide a way to quantify this disruption and assess whether a therapeutic intervention meaningfully improves symptom expression rather than simply reducing inflammation markers.
Similar challenges arise in inflammatory diseases affecting internal organs, including the lung. In conditions such as asthma or fibrotic lung disease, tissue inflammation or remodeling does not consistently predict functional limitation. Patients with comparable pathological or biological findings (such as blood Immunoglobulin E levels) may experience very different impacts on breathing capacity, exercise tolerance, or symptom control. From a preclinical perspective, this highlights the value of functional assessments that probe respiratory mechanics, activity levels, or sensitivity to physiological stress (e.g. plethysmography), offering insight into how inflammation alters organ performance over time.
Endometriosis provides a further illustration of why functional readouts matter. Clinically, lesion burden and anatomical distribution correlate poorly with patient impact, and especially pain. Small or localized lesions can result in profound functional impairment, while extensive disease may be associated with relatively limited disruption. This reinforces the limitations of relying solely on lesion-centric endpoints and underscores the need to consider functional consequences alongside structural measures.
Preclinical research increasingly reflects this complexity by incorporating behavioral, sensory, and physiological assessments into study design. While these approaches are inherently indirect, they allow researchers to interrogate how inflammatory processes affect function at the system level. When interpreted alongside histological and molecular data, functional readouts help distinguish between biological activity and meaningful therapeutic effect.
Taken together, this approach supports a broader shift in inflammatory disease modelling. Translational success depends not only on modifying pathological markers, but on demonstrating that those changes translate into functional improvement. By integrating functional assessments into preclinical studies, researchers can better align experimental outcomes with patient experience, bridging the gap between inflammation as a biological process and inflammation as a lived disease.
Considerations when planning functional endpoints in inflammation studies.
As inflammation research continues to evolve, study design increasingly needs to reflect not just biological activity, but functional relevance. When planning preclinical inflammation studies, several considerations can help ensure that experimental outcomes remain aligned with patient experience:
- Define impact early. Clarify what functional disruption caused by the disease is intended to be modeled (e.g. sensory discomfort such as itching, behavioral alteration, or organ-level impairment) before selecting endpoints.
- Avoid single-endpoint dependence. Structural or histological measures alone may not capture meaningful therapeutic effects. Combining anatomical, molecular, and functional readouts provides a more complete view of disease modulation.
- Match function to tissue context. Inflammatory processes manifest differently across skin, lung, and visceral tissues. Functional assessments should reflect the biological role of the affected organ system.
- Interpret functional data in context. Behavioural and physiological readouts are indirect by nature and require careful interpretation alongside pathology and mechanistic data.
- Prioritise translational relevance. Endpoints that mirror how disease affects daily function can improve confidence that preclinical findings will translate beyond the laboratory.
- Consider variability carefully. Functional readouts tend to be more variable than biological readouts. Group size must be adjusted to the expected variability of the envisioned functional readout to provide statistically strong data.
Incorporating functional considerations into inflammation studies strengthens pathology-driven approaches, linking measurable disease biology with the symptomatic burden experienced by clinical trial subjects and patients.
Five questions to ask your study director during study design:
When designing preclinical studies in inflammatory disease, early dialogue around endpoints can shape not only the data generated, but how confidently that data can be interpreted. Asking the following questions can help ensure that functional relevance is considered alongside traditional pathological measures:
- What functional consequences of inflammation are most relevant in this disease context?
Beyond tissue pathology, which aspects of function (sensory, behavioural, or physiological) best reflect disease impact? - How well do proposed endpoints capture patient-relevant disruption?
Are readouts aligned with how the disease affects daily life, rather than relying solely on anatomical or molecular change? - Which functional assessments are appropriate for the target tissue?
Functional manifestations differ across skin, lung, visceral inflammation etc; endpoint selection should reflect organ-specific biology. - How will functional and structural data be interpreted together?
Is there a clear strategy for integrating behavioral or physiological findings with histology and biomarker data? - What level of change would be considered biologically meaningful?
How will improvements in function be distinguished from variability inherent to indirect readouts?
Asking these questions early can help ensure that preclinical inflammation studies generate data that genuinely supports translational decision-making.
Functional endpoints do not replace established measures of disease biology, but they can provide critical context that helps bridge the gap between inflammatory mechanisms and the outcomes that will matter most in the clinic.
Interested in talking to our inflammation team about study design and model selection? Get in touch with us to learn more.
